Dr Reddys Chairman Satish Reddy named as New President of Indian Pharmaceutical Alliance
Dr Reddy's Labs' Chairman, Satish Reddy played a key role in shaping policies concerning the pharmaceutical sector as well as the economy, such as policy formulation on India's patent law, drug pricing and important amendments to the Drugs & Cosmetics Act.
New Delhi: Mr Satish Reddy, Chairman of Dr Reddy’s Laboratories has been appointed as President of the IPA for 2019-2021. Dr Rajesh Jain, Managing Director of Panacea Biotec Limited will continue as the Vice President.
Mr Satish Reddy holds a degree in Chemical Engineering from Osmania University, India, and an M.S. in Medicinal Chemistry from Purdue University, USA, where he received the 2009 Distinguished Alumnus Award from the School of Pharmacy and Pharmaceutical Sciences.
As an active member of major industry associations and governmental panels, Mr Reddy played a key role in shaping policies concerning the pharmaceutical sector as well as the economy, such as policy formulation on India's patent law, drug pricing and important amendments to the Drugs & Cosmetics Act.
He was a past president of IPA (2013-2015), a member of the Drugs Technical Advisory Board of India, the Chairman of the Andhra Pradesh Chapter of the Confederation of Indian Industries (CII) and head of its National Committee on Pharmaceuticals.
Also Read: Indian Pharma aspiring to grow to 120-130 billion Dollar Industry by 2030: IPA
Mr Reddy, currently Chairs the Life Sciences Skill Development Council under the National Skill Development Corporation (NSDC). In addition, he is Chairman of Dr Reddy’s Foundation.
Satish Reddy led Dr Reddy’s transition from a uni-focused manufacturer of APIs (active pharmaceutical ingredients) to a company that moved up the value chain with a diverse product portfolio of Finished Dosage Formulations. He oversaw the expansion and establishment of a strong footprint for Dr Reddy's finished dosage products in the US, Russia, CIS countries and other emerging markets.
Dr Rajesh Jain is Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people. He provides strategic leadership, management and guidance to the company. He has extensive experience and qualifications in biotechnology and is responsible for Innovation and Business Development.
Dr Jain is a science graduate and holds a PhD in Management. He has authored two position papers for CII: Guideline Changes in Vaccine Approval Procedures and Regulatory & Policy Changes for Sustained Competitiveness of the Indian Vaccine Industry.
Dr Jain is an active member of major industry associations and government panels. He is Chairman -Confederation of Indian Industry (CII), National Committee on Biotechnology for 2019-20. He is a member of the Central Drug Research Institute (CDRI), Lucknow.
Dr Jain is a recipient of many awards such as India Innovation Award for 2016 and 2015 by Clarivate Analytics and has been appreciated by GAVI and Bill and Melinda Gates Foundation for his commitment towards making affordable vaccines for population across the globe.
At the time when the pharmaceutical industry is undergoing a critical phase of its growth and development, foresight and acumen of leadership will be of immense value to the IPA, in particular, and to the national industry, in general.
Also Read: Indian pharma industry may achieve double-digit growth by 2030 via regulatory support from Government, says pharma industry body